Journal Article

IDS Bulletin 49.2

Accountability and Generating Evidence for Global Health: Misoprostol in Nepal

Published on 8 May 2018

Postpartum haemorrhage (PPH) is a major cause of maternal morbidity and mortality in Nepal. Compounded by the remote terrain, endemic poverty, and a lack of access to health facilities, the use of misoprostol has advantages over the standard use of oxytocin for PPH management.

Drawing on our qualitative study of a pilot intervention managed by the Nepal Family Health Programme, we map the institutional relationships involved in the design, implementation, and practices for bringing misoprostol into national policy. In the intense and competitive global and national policy arena, sustained lobbying and getting the ‘right people’ on board were as powerful drivers as the quality of the intervention itself. The case study takes us to the heart of the debate around the politics of generation of evidence for interventions in global health programmes, and ultimately the question of accountability for health policy and practice.

Related Content

This article comes from the IDS Bulletin 49.3 (2018) Accountability and Generating Evidence for Global Health: Misoprostol in Nepal

Cite this publication

Raj Sharma, J., Khatri, R. and Harper, I. (2018) 'Accountability and Generating Evidence for Global Health: Misoprostol in Nepal' in Nelson, E., Bloom, G and Shankland, A. (Eds) Accountability for Health Equity: Galvanising a Movement for Universal Health Coverage, IDS Bulletin 49.2, Brighton: IDS

Authors

Raj Sharma Jeevan
Rekha Khatri
Ian Harper

Publication details

published by
Institute of Development Studies
doi
10.19088/1968-2018.135
language
English

Share

About this publication

Region
Nepal

Related content

Brief

Key Considerations: Post-Trauma Impacts in Conflict-Affected Communities in Northern Nigeria

SSHAP Briefing

Ayodele Samuel Jegede & 2 others

8 November 2024

Brief

SSHAP West Africa Hub: Addressing the Kush Epidemic in Sierra Leone

SSHAP Briefing

4 November 2024